INCANNEX HEALTHCARE INC (IXHL) Fundamental Analysis & Valuation

NASDAQ:IXHL • US45333F1093

3.08 USD
-2.89 (-48.41%)
At close: Mar 12, 2026
3.1 USD
+0.02 (+0.65%)
After Hours: 3/12/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IXHL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, IXHL scores 4 out of 10 in our fundamental rating. IXHL was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for IXHL as it has an excellent financial health rating, but there are worries on the profitability. IXHL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. IXHL Profitability Analysis

1.1 Basic Checks

  • In the past year IXHL has reported negative net income.
  • IXHL had a negative operating cash flow in the past year.
  • IXHL had negative earnings in each of the past 5 years.
  • In the past 5 years IXHL always reported negative operating cash flow.
IXHL Yearly Net Income VS EBIT VS OCF VS FCFIXHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • IXHL's Return On Assets of -62.51% is on the low side compared to the rest of the industry. IXHL is outperformed by 67.36% of its industry peers.
  • IXHL's Return On Equity of -63.87% is in line compared to the rest of the industry. IXHL outperforms 43.52% of its industry peers.
Industry RankSector Rank
ROA -62.51%
ROE -63.87%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IXHL Yearly ROA, ROE, ROICIXHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

1.3 Margins

  • IXHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IXHL Yearly Profit, Operating, Gross MarginsIXHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K -250K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IXHL Health Analysis

2.1 Basic Checks

  • IXHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IXHL Yearly Shares OutstandingIXHL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
IXHL Yearly Total Debt VS Total AssetsIXHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • An Altman-Z score of 772.06 indicates that IXHL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of IXHL (772.06) is better than 99.48% of its industry peers.
  • There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 772.06
ROIC/WACCN/A
WACCN/A
IXHL Yearly LT Debt VS Equity VS FCFIXHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 48.27 indicates that IXHL has no problem at all paying its short term obligations.
  • IXHL has a better Current ratio (48.27) than 98.96% of its industry peers.
  • IXHL has a Quick Ratio of 48.27. This indicates that IXHL is financially healthy and has no problem in meeting its short term obligations.
  • IXHL has a Quick ratio of 48.27. This is amongst the best in the industry. IXHL outperforms 98.96% of its industry peers.
Industry RankSector Rank
Current Ratio 48.27
Quick Ratio 48.27
IXHL Yearly Current Assets VS Current LiabilitesIXHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IXHL Growth Analysis

3.1 Past

  • The earnings per share for IXHL have decreased strongly by -19.16% in the last year.
  • Looking at the last year, IXHL shows a very strong growth in Revenue. The Revenue has grown by 616.67%.
  • Measured over the past years, IXHL shows a very negative growth in Revenue. The Revenue has been decreasing by -36.33% on average per year.
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, IXHL will show a very strong growth in Earnings Per Share. The EPS will grow by 42.45% on average per year.
  • The Revenue is expected to grow by 1900.01% on average over the next years. This is a very strong growth
EPS Next Y97.08%
EPS Next 2Y42.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IXHL Yearly Revenue VS EstimatesIXHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2027 20M 40M 60M
IXHL Yearly EPS VS EstimatesIXHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. IXHL Valuation Analysis

4.1 Price/Earnings Ratio

  • IXHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 48.89 indicates a quite expensive valuation of IXHL.
  • IXHL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IXHL is cheaper than 69.95% of the companies in the same industry.
  • IXHL's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.82.
Industry RankSector Rank
PE N/A
Fwd PE 48.89
IXHL Price Earnings VS Forward Price EarningsIXHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IXHL Per share dataIXHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as IXHL's earnings are expected to grow with 42.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.45%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IXHL Dividend Analysis

5.1 Amount

  • No dividends for IXHL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IXHL Fundamentals: All Metrics, Ratios and Statistics

INCANNEX HEALTHCARE INC

NASDAQ:IXHL (3/12/2026, 8:00:03 PM)

After market: 3.1 +0.02 (+0.65%)

3.08

-2.89 (-48.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13
Earnings (Next)05-13
Inst Owners1.07%
Inst Owner Change149.46%
Ins Owners12.79%
Ins Owner Change91.78%
Market Cap1.07B
Revenue(TTM)86.00K
Net Income(TTM)-46.88M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.5%
Min EPS beat(2)36.5%
Max EPS beat(2)36.5%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 48.89
P/S 12399.87
P/FCF N/A
P/OCF N/A
P/B 14.53
P/tB 14.53
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)0.06
Fwd EY2.05%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.51%
ROE -63.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 48.27
Quick Ratio 48.27
Altman-Z 772.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.79%
EPS Next Y97.08%
EPS Next 2Y42.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.16%
OCF growth 3YN/A
OCF growth 5YN/A

INCANNEX HEALTHCARE INC / IXHL FAQ

What is the ChartMill fundamental rating of INCANNEX HEALTHCARE INC (IXHL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IXHL.


Can you provide the valuation status for INCANNEX HEALTHCARE INC?

ChartMill assigns a valuation rating of 2 / 10 to INCANNEX HEALTHCARE INC (IXHL). This can be considered as Overvalued.


What is the profitability of IXHL stock?

INCANNEX HEALTHCARE INC (IXHL) has a profitability rating of 0 / 10.